Dr. Haiyan Yang 杨海燕
Chief Physician
Department of Lymphoma Medical Oncology, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of various types of lymphoma, multiple myeloma, and chronic lymphocytic leukemia.
Dr. Yang holds a medical doctorate from Soochow University (2007) and completed advanced training at Peking University Cancer Hospital (2010). The physician focuses on chemotherapy for common malignancies, particularly hematologic tumors. Research interests include standardized diagnosis and treatment of malignant lymphoma. Dr. Yang has published six papers and led or participated in multiple provincial-level research projects.
Professional roles
- Member, Zhejiang Committee of Integrated Traditional Chinese and Western Medicine Hematology Professional Committee, Chinese Medical Association
Name order: in Chinese the family name comes first (Yang Haiyan). Papers usually list the name as Haiyan Yang or Yang H.
Selected publications
84 papers on PubMed matched by name and affiliation; 18 as first or senior author since 2016. Most recent first- or senior-author papers:
- Biomark Res, 2026 (senior author): Genetic orchestration of the primary central nervous system lymphoma microenvironment. PubMed 42811343
- Blood Adv, 2026 (senior author): Selinexor combined with R-CHOP achieved a high response rate in newly diagnosed double/triple-hit lymphoma. PubMed 42480213
- Am J Hematol, 2026 (senior author): RCLARITY: A Prospective Phase II Study of Rituximab Combined With Lenalidomide and Chidamide (RLC) for the Treatment of Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma. PubMed 42124356
- Eur J Med Chem, 2026 (senior author): The double-edged sword of pyroptosis targeting in cancer therapy. PubMed 41865598
- Eur J Med Chem, 2025 (senior author): Recent advances in functional activatable probes for oncological surgery: Illuminating precision or hindering clinical translation?. PubMed 40617197
- Bioorg Chem, 2025 (senior author): Discovery and characterization of sulfonamide derivatives as transcriptional enhanced associate domain (TEAD) inhibitors: a novel approach for targeting hepatocellular carcinoma. PubMed 40913956
- BMC Cancer, 2023 (senior author): Peripheral immune cell profiling of double-hit lymphoma by mass cytometry. PubMed 36823603
- Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2023 (senior author): [Newest Advances in Diagnosis and Treatment of Plasmablastic Lymphoma --Review]. PubMed 37846723
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion